Skip to content

Pricing and reimbursement of drugs and medical devices in Hungary

by Laszlo Gulácsi, T. Dávid, Cs Dózsa
European Journal of Health Economics ()
Get full text at journal


Similarly to other countries of Central and Eastern Europe, Hungary has witnessed massive diffusion of healthcare technology such as drugs and medical devices since 1990. While substantial new pharmaceuticals, medical devices, and procedures have been liberalized, there has been no proper evaluation or training in their use. Healthcare providers have come to find themselves as entrepreneurs in private practice, while patients are acquiring an increasing awareness as customers of healthcare,demanding services in return for their taxes and contributions. This has led to extremely irrational patterns of investment in technology, with most an obvious waste of resources, while leaving basic needs unmet. Both the National Health Insurance Fund and the Ministry of Finance believe that the current pharmaceutical and medical device bill is too high. However, introducing a more transparent and flexible pricing and reimbursement framework may enable a more efficient allocation of the limited resources to be achieved.

Cite this document (BETA)

Readership Statistics

18 Readers on Mendeley
by Discipline
44% Medicine and Dentistry
22% Economics, Econometrics and Finance
11% Pharmacology, Toxicology and Pharmaceutical Science
by Academic Status
22% Other
22% Researcher
17% Student > Master
by Country
6% India
6% Germany

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in